|
|
|
|
Executive Moves: Avma Pharma Solutions
Thomas M.Salus has been appointed vice president, contract services, , a division of PL Developments, and Richard Thome has been named senior vice president, operations of both PL Developments and. Salus will be responsible for managing...
|
|
|
Galapagos Earns GSK Milestones
Galapagos NV has successfully achieved a pre-clinical candidate drug in its osteoarthritis alliance with GlaxoSmithKline.Galapagos also reached milestones on other compounds in the alliance, earning milestone payments totaling $10.
|
|
|
Executive Moves: Valeant Pharmaceuticals
Rajiv De Silva has been appointed chief operating officer of Specialty Pharmaceuticals, , effective January 5, 2009.De Silva will be responsible for overseeing the U.S., Canadian and Australian specialty pharmaceuticals operations. 'We...
|
|
|
PPD, Merck Enter Vax-Lab Pact
PPD, Inc.has purchased Mercks 130,000-sq.-ft.vaccine testing lab and related equipment in Wayne, PA and hired the 80 Merck employees who operate the facility. PPD will provide assay development and immunogenicity testing services to...
|
|
|
DOR Gets SPA Clearance for orBec Trial
DOR BioPharma, Inc.has reached agreement with the FDA on the design of a confirmatory Phase III trial for its lead product orBec for the treatment of acute gastrointestinal Graft-versus-Host Disease (GI GVHD).The agreement was made under...
|
|
|
Executive Moves: Xoma, Ltd
Fred Kurland has been appointed vice president, finance and chief financial officer at Xoma, Ltd.Kurland will be responsible for directing the company's financial strategy, accounting, financial planning and investor relations functions....
|
|
|
Nektar Sells Pulmonary Delivery Assets to Novartis
Nektar Therapeutics has sold some of its pulmonary delivery assets, technology, and intellectual property to Novartis for $115 million in cash.Novartis now owns 'certain dry powder and liquid pulmonary formulation and manufacturing assets...
|
|
|
Executive Moves: Hovione
Roger Viney, Ph.has been named director of sales & marketing Europe and Asia for Hovione. Thomas Eisele, Ph. has been named general manager R&D at the company and Steve Beagle has been named director of sales &...
|
|
|
King Starts Phase II for Pain Drug
King Pharmaceuticalshas initiated the Phase II trial evaluating the efficacy and safety of T-62, an investigational drug for the treatment of neuropathic pain.Eric Carter, chief science officer of King, remarked, T-62, a new chemical...
|
|
|
Actavis Reaches Consent Degree Over NJ Facilities
Actavis Inc.has reached agreement with the FDA on a Consent Decree of Permanent Injunction the companys Actavis Totowa LLC subsidiary.This agreement, in effect, settles the issues identified by the Department of Justice in its previously...
|
